- Immutep (IMM) completes recruitment for its phase II study for non-small cell lung cancer
- The last patient has now been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study
- Patients are now participating across three parts of the study, in 20 clinical sites in Australia, Europe and the US
- The company says its clinical team and partners have worked hard to continue the pace of patient enrolment and finished recruitment earlier than originally anticipated
- Immutep is up 0.92 per cent, trading at 55 cents at 11:20 am AEDT
Immutep (IMM) has completed recruitment for its phase II study for in non-small cell lung cancer.
The last patient has now been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study.
The study is being conducted in collaboration with Merck & Co to evaluate the combination of eftilagimod alpha (efti) with KEYTRUDA in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in the first and second line.
A total of 185 patients are now participating across three parts of the study, in 20 clinical sites in Australia, Europe and the US.
The company said Part A was completed faster than anticipated, with all patients recruited in under 12 months.
Immutep CEO, Marc Voigt, said the completion of recruitment marks a major milestone for the company.
“Our clinical team and partners have worked hard to continue the pace of patient enrolment and finished recruitment much earlier than originally anticipated, despite some challenging conditions brought on by the COVID-19 pandemic,” Mr Voigt said.
“We are excited to be reporting further results from this trial in the coming months.”
Immutep was up 0.92 per cent, trading at 55 cents at 11:20 am AEDT.